Abstract
Lung cancer is the leading cause of cancer deaths in the United States and Europe. Tyrosine kinases, involved in signal transduction pathways, are frequently mutated in lung cancer, and novel therapeutic interventions have substantially improved the outcome for patients whose tumors have detectable mutations. The discoidin domain receptors (DDRs) are members of the receptor tyrosine kinase (RTK) family. They are activated by collagen, and mounting evidence from biological model systems suggests key roles for these receptors in tumor cell invasion, migration, and metastatic spread. Several investigations have described associations between expression levels or mutations of DDRs and patients’ survival and response to therapy. However, results from these studies are inconsistent and sometimes contradictory, which may be explained by differences in the use of analytic methods, the retrospective nature of study reports, and differences in biospecimen procurement, storage, and processing.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Shaw AT, Kim D-W, Mehra R et al (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:1189–1197
Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R (2012) Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev 31:295–321
Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF (2007) Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 96:808–814
Yang SH, Baek HA, Lee HJ et al (2010) Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep 24:311–319
Miao L, Zhu S, Wang Y et al (2013) Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med Oncol 30:626
Valencia K, Ormazabal C, Zandueta C et al (2012) Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res 18:969–980
Payne LS, Huang PH (2014) Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J Thorac Oncol 9:900–904
Ren T, Zhang J, Zhang J, Liu X, Yao L (2013) Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Med Oncol 30:397
Ren T, Zhang W, Liu X et al (2014) Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia. J Pathol 234:526–537
Zhang K, Corsa CA, Ponik SM et al (2013) The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol 15:677–687
Yan Z, Jin S, Wei Z et al (2014) Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein. Biochim Biophys Acta 1842:1350–1363
Xu J, Lu W, Zhang S et al (2014) Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma. Cancer Biol Ther 15:612–622
Sasaki H, Shitara M, Yokota K et al (2012) DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. Oncol Lett 4:33–37
Miao L, Wang Y, Zhu S et al (2014) Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. BMC Cancer 14:369
Kim D, Ko P, You E, Rhee S (2014) The intracellular juxtamembrane domain of discoidin domain receptor 2 (DDR2) is essential for receptor activation and DDR2-mediated cancer progression. Int J Cancer 135:2547–2557
Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190–1203
Ruiz PA, Jarai G (2011) Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem 286:12912–12923
Iwai LK, Payne LS, Luczynski MT et al (2013) Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem J 454:501–513
Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075
Davies H, Hunter C, Smith R et al (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65:7591–7595
Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 1:78–89
Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G (2013) Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer 82:171–172
Reungwetwattana T, Dy GK (2013) Targeted therapies in development for non-small cell lung cancer. J Carcinog 12:22
Beauchamp EM, Woods BA, Dulak AM et al (2014) Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther 13:475–482
Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070–2075
Bai Y, Kim JY, Watters JM et al (2014) Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res 74:7217–7228
Bollig-Fischer A, Chen W, Gadgeel SM et al (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250–255
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Zhang, Y., Malysa, A., Bepler, G. (2016). Discoidin Domain Receptors in Lung Cancer. In: Fridman, R., Huang, P. (eds) Discoidin Domain Receptors in Health and Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6383-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6383-6_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-6381-2
Online ISBN: 978-1-4939-6383-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)